Clinical Evidence

The Research Behind Our Protocols

Every treatment we offer is grounded in published, peer-reviewed human clinical data.

Landmark Studies

Key Clinical Publications

A selection of the most clinically significant studies informing our protocols.

Hernigou & Beaujean — Clinical Orthopaedics & Related Research, 2002

Treatment of Osteonecrosis with Autologous Bone Marrow Grafting

189 hips, 116 patients. Core decompression + BMA injection. 5–10 year follow-up. CFU count was the primary determinant of outcome.

94% success — Stage I & II AVN
Hernigou et al. — JBJS, 2005

Percutaneous Autologous Bone Marrow Grafting for Non-Unions

60 tibial non-union patients. >1,500 CFU/cc achieved 100% union. <1,000 CFU/cc = failure. No complications.

88.3% bone union rate
Gangji et al. — JBJS, 2004

Treatment of Osteonecrosis of the Femoral Head — Controlled Study

18 hips, 13 patients. Double-blind controlled trial. BMA group: 1 of 10 progressed to Stage III. Control: 5 of 8 progressed. Necrotic lesion reduced 35% at 24 months.

90% — Stage I & II success
Hernigou et al. — International Orthopaedics, 2014

Biologic Augmentation of Rotator Cuff Repair with MSCs

90 patients (45 BMA / 45 control). Prospective, controlled. Single-row repair + BMAC injection. CFU count was the most relevant outcome predictor.

100% vs. 67% at 6 months; 87% vs. 44% at 10 years
Kuebler et al. — Stem Cells International, 2022

Short-Term Outcomes Using Novel Aspiration Technique for Knee OA

174 patients, 267 knees. Single Marrow Cellution BMA injection. Statistically significant WOMAC and VAS improvements at 6 months.

p < 0.001 — VAS & WOMAC
Dwyer et al. — Arthroscopy Sports Med Rehabil, 2021

BMA Injection for Glenohumeral Joint OA — Pilot RCT

22 patients, 25 shoulders. BMA vs. cortisone. BMA demonstrated superior Quick-DASH and EQ-5D-5L pain scores at 12-month follow-up.

Superior outcomes vs. cortisone at 12 months
Mazzanti et al. — Harvest vs. Aspire AGO Analysis

BMA for Critical Limb Ischemia — Marrow Cellution vs. Harvest

Marrow Cellution: 5.3% amputation rate, 0% death. Harvest centrifuge: 34.5% amputation, 8.6% death.

5.3% vs. 34.5% amputation rate
Bieri et al. — Journal of Translational Medicine, 2020

Autologous BMA in PDE5-Inhibitor Refractory Erectile Dysfunction

Marrow Cellution: 3,160±297 CFU/mL vs. Magellan 506±102 CFU/mL. ED index 3× better for Marrow Cellution group.

3× ED index improvement

Want to Discuss the Research?

Our physicians are happy to walk you through the clinical evidence as it applies to your specific condition.

Schedule a Consultation